(Q36596818)

15 August 2017

4 references

22 March 2019

7 November 2019

4 December 2020

17 December 2020

Review of bosentan in the management of pulmonary arterial hypertension (English)

1 reference

15 August 2017

pulmonary hypertension

2 references

22 March 2019

7 November 2019

1 reference

7 November 2019

antihypertensive drug

1 reference

4 December 2020

1 reference

17 December 2020

Eli Gabbay

1

1 reference

15 August 2017

John Fraser

series ordinal

2

1 reference

15 August 2017

Keith McNeil

series ordinal

3

1 reference

15 August 2017

language of work or name

English

0 references

publication date

1 January 2007

1 reference

Vascular Health and Risk Management

15 August 2017

5 references

15 August 2017

22 March 2019

7 November 2019

4 December 2020

17 December 2020

3

1 reference

15 August 2017

6

1 reference

15 August 2017

887-900

1 reference

Sitaxsentan in the management of pulmonary arterial hypertension

15 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2350123

Current and future management of chronic thromboembolic pulmonary hypertension: from diagnosis to treatment responses.

9 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2350123

Bosentan treatment for pulmonary arterial hypertension related to connective tissue disease: a subgroup analysis of the pivotal clinical trials and their open-label extensions.

9 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2350123

Systemic sclerosis associated pulmonary hypertension: improved survival in the current era.

9 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2350123

Sildenafil citrate therapy for pulmonary arterial hypertension

9 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2350123

Long-term outcome of bosentan treatment in idiopathic pulmonary arterial hypertension and pulmonary arterial hypertension associated with the scleroderma spectrum of diseases

9 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2350123

Survival in patients with class III idiopathic pulmonary arterial hypertension treated with first line oral bosentan compared with an historical cohort of patients started on intravenous epoprostenol

9 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2350123

Bosentan decreases the plasma concentration of sildenafil when coprescribed in pulmonary hypertension

9 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2350123

Survival with first-line bosentan in patients with primary pulmonary hypertension.

9 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2350123

Treatment of pulmonary arterial hypertension

9 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2350123

Comparative analysis of clinical trials and evidence-based treatment algorithm in pulmonary arterial hypertension

9 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2350123

Cellular and molecular pathobiology of pulmonary arterial hypertension

9 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2350123

Clinical classification of pulmonary hypertension.

9 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2350123

Inhaled iloprost for severe pulmonary hypertension

9 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2350123

Continuous subcutaneous infusion of treprostinil, a prostacyclin analogue, in patients with pulmonary arterial hypertension: a double-blind, randomized, placebo-controlled trial.

9 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2350123

Mutation in the gene for bone morphogenetic protein receptor II as a cause of primary pulmonary hypertension in a large kindred

9 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2350123

9 September 2017

Endothelin antagonists

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2350123

Acute pro-inflammatory actions of endothelin-1 in the guinea-pig lung: involvement of ETA and ETB receptors

9 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2350123

Different electrical responses to vasoactive agonists in morphologically distinct smooth muscle cell types

9 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2350123

Chronic major-vessel thromboembolic pulmonary hypertension

9 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2350123

Inhaling nitric oxide: a selective pulmonary vasodilator and bronchodilator

9 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2350123

Public funding of bosentan for the treatment of pulmonary artery hypertension in Australia: cost effectiveness and risk sharing

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2350123

A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension

28 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2350123

Pulmonary vasodilation with prostacyclin in primary and secondary pulmonary hypertension.

28 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2350123

Survival in patients with primary pulmonary hypertension. Results from a national prospective registry.

28 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2350123

The effect of high doses of calcium-channel blockers on survival in primary pulmonary hypertension

28 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2350123

Quality of life in pulmonary arterial hypertension: improvement and maintenance with bosentan.

28 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2350123

First experience with an oral combination therapy using bosentan and sildenafil for pulmonary arterial hypertension.

20 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2350123

Long-term outcome with first-line bosentan therapy in idiopathic pulmonary arterial hypertension.

20 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2350123

Goal-oriented treatment and combination therapy for pulmonary arterial hypertension

20 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2350123

Bosentan therapy for inoperable chronic thromboembolic pulmonary hypertension.

20 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2350123

Bosentan therapy for inoperable chronic thromboembolic pulmonary hypertension

20 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2350123

Effects of long-term bosentan in children with pulmonary arterial hypertension.

20 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2350123

Bosentan in inoperable chronic thromboembolic pulmonary hypertension.

20 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2350123

Combination therapy with bosentan and sildenafil in idiopathic pulmonary arterial hypertension

20 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2350123

Combination of bosentan with epoprostenol in pulmonary arterial hypertension: BREATHE-2.

20 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2350123

Bosentan for the treatment of human immunodeficiency virus-associated pulmonary arterial hypertension

20 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2350123

Diagnosis and management of pulmonary arterial hypertension: ACCP evidence-based clinical practice guidelines

20 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2350123

Continuous intravenous epoprostenol for chronic thromboembolic pulmonary hypertension

20 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2350123

Pulmonary endarterectomy: experience and lessons learned in 1,500 cases

20 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2350123

Effects of the dual endothelin receptor antagonist bosentan in patients with pulmonary arterial hypertension: a 1-year follow-up study

20 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2350123

Pharmacokinetics, safety, and efficacy of bosentan in pediatric patients with pulmonary arterial hypertension

20 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2350123

Effects of the oral endothelin-receptor antagonist bosentan on echocardiographic and doppler measures in patients with pulmonary arterial hypertension.

20 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2350123

Long-term intravenous epoprostenol infusion in primary pulmonary hypertension: prognostic factors and survival.

20 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2350123

Effects of the dual endothelin-receptor antagonist bosentan in patients with pulmonary hypertension: a randomised placebo-controlled study

20 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2350123

Heterozygous germline mutations in BMPR2, encoding a TGF-beta receptor, cause familial primary pulmonary hypertension

20 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2350123

Expression of endothelin-1 in the lungs of patients with pulmonary hypertension.

20 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2350123

Bosentan therapy in patients with Eisenmenger syndrome: a multicenter, double-blind, randomized, placebo-controlled study

20 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2350123

Guidelines on diagnosis and treatment of pulmonary arterial hypertension. The Task Force on Diagnosis and Treatment of Pulmonary Arterial Hypertension of the European Society of Cardiology

21 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2350123

Combination therapy for pulmonary arterial hypertension: still more questions than answers

4 December 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2350123

Conversion to Bosentan From Prostacyclin Infusion Therapy in Pulmonary Arterial Hypertension

4 December 2018

1 reference

12 December 2020

Randomized study of adding inhaled iloprost to existing bosentan in pulmonary arterial hypertension

1 reference

12 December 2020

International guidelines for the selection of lung transplant candidates. The American Society for Transplant Physicians (ASTP)/American Thoracic Society(ATS)/European Respiratory Society(ERS)/International Society for Heart and Lung Transplantation

1 reference

12 December 2020

Primary pulmonary hypertension

1 reference

12 December 2020

Pulmonary arterial hypertension: are we doing enough to identify systemic sclerosis patients at high risk of this rare condition?

1 reference

12 December 2020

Treatment for secondary pulmonary hypertension

1 reference

12 December 2020

Bosentan therapy for pulmonary arterial hypertension

1 reference

12 December 2020

Pulmonary hypertension in collagen vascular disease

1 reference

12 December 2020

Primary pulmonary hypertension

1 reference

12 December 2020

Surgical treatments/interventions for pulmonary arterial hypertension: ACCP evidence-based clinical practice guidelines

1 reference

12 December 2020

Pulmonary Arterial Hypertension

1 reference

12 December 2020

Primary pulmonary hypertension: natural history and the importance of thrombosis

1 reference

12 December 2020

The endothelin ETB receptor mediates both vasodilation and vasoconstriction in vivo

1 reference

12 December 2020

Endothelin receptors in cultured adult rat cardiac fibroblasts

1 reference

12 December 2020

1 reference

12 December 2020

Bosentan for the treatment of pulmonary arterial hypertension associated with congenital cardiac disease

1 reference

12 December 2020

The efficacy of bosentan in inoperable chronic thromboembolic pulmonary hypertension: a 1-year follow-up study

1 reference

12 December 2020

Identifiers

1 reference

15 August 2017

PubMed publication ID

18200808

1 reference